We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Double-Blind Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00334399
First Posted: June 7, 2006
Last Update Posted: October 10, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Sanwa Kagaku Kenkyusho Co., Ltd.
  Purpose
The purpose of this study is to evaluate the clinical efficacy and safety of Miglitol in patients with Type2 Diabetes Mellitus treated with Biguanide.

Condition Intervention Phase
Type 2 Diabetes Mellitus Drug: Miglitol Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Sanwa Kagaku Kenkyusho Co., Ltd.:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 69 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 2 diabetic patients treated with Biguanide
  • Criteria for postprandial plasma glucose and HbA1c are met

Exclusion Criteria:

  • Type 1 diabetes
  • Patients treated with other antidiabetic drugs or Insulin
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00334399


Locations
Japan
Aichi, Japan
Chiba, Japan
Fukuoka, Japan
Gifu, Japan
Gunma, Japan
Hokkaido, Japan
Ibaragi, Japan
Kanagawa, Japan
Kumamoto, Japan
Miyazaki, Japan
Osaka, Japan
Saitama, Japan
Tochigi, Japan
Sponsors and Collaborators
Sanwa Kagaku Kenkyusho Co., Ltd.
Investigators
Study Director: Clinical Study Group, Clinical Development Dept. Sanwa Kagaku Kenkyusho Co., Ltd.
  More Information

ClinicalTrials.gov Identifier: NCT00334399     History of Changes
Other Study ID Numbers: MG1008
First Submitted: May 26, 2006
First Posted: June 7, 2006
Last Update Posted: October 10, 2008
Last Verified: October 2008

Keywords provided by Sanwa Kagaku Kenkyusho Co., Ltd.:
alpa-glucosidase inhibitor,Biguanide

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Miglitol
Biguanides
Hypoglycemic Agents
Physiological Effects of Drugs
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Glycoside Hydrolase Inhibitors